The medical use of ketamine to alleviate symptoms of depression carries a low risk of addiction, suggests new research from the University of Geneva (UNIGE).
Biopharmaceutical company Silo Pharma has carried out an animal study investigating the topical administration of ketamine for pain reduction.
COMPASS Pathways has launched its multi-centre, doubleblind randomised controlled Phase 2 clinical trial investigating the efficacy of its proprietary formulation of synthetic psilocybin, COMP360, in people...
Psyched Wellness has announced preliminary data from tests completed by the National Research Council of Canada (NRC) on its extract AME-1.
The UNC School of Medicine has found that variants in one serotonin receptor in neurons could be why some patients fare much better after psychedelic therapy...
In a move that aims to provide patients in Canada with the “life-changing opportunity” to receive psilocybin-assisted psychotherapy, TheraPsil and Drug Science are collaborating to launch...
UK-based Small Pharma has announced that its DMT patent strategy has been strengthened with a new US patent protection on injectable DMT delivery in its lead...
The Phase II clinical trial will test the efficacy of psilocybin on treatment resistant Post Traumatic Stress Disorder (PTSD).
B.More has submitted an Investigational New Drug (IND) application for its Psilocybin Alcohol Use Disorder Programme.
Field Trip has now completed the dosing of the first patients in its Phase 1 clinical study: A double-blind, randomised, placebo-controlled study to investigate the safety,...